Düzeltme: X'e bağlı agamaglobulinemi hastalarında uygulanan COVID-19 tedavi prosedürleri

Yıl 2024, Cilt: 3 Sayı: 1, 40 - 47, 30.04.2024

Hatice Köse , İhsan Ciftci , Ayten Gündüz

Bu makalenin ilk hali 23 Aralık 2022 tarihinde yayımlandı. https://dergipark.org.tr/tr/pub/jomtu/issue/74065/1137147

Düzeltme Notu

Hatice Köse isimli araştırmacının kurumu "Sakarya Üniversitesi, Sağlık Bilimleri Enstitüsü, Tıbbi Mikrobiyoloji Anabilim Dalı, Malatya, Türkiye" olarak sehven yazılmıştır. Kurum yeri Sakarya, Türkiye olarak düzeltilmiştir.

Öz

Amaç: COVID-19 pandemisi 2019 yılında başlayan ve birçok kişinin ölümüne neden olan küresel bir salgındır. X'e bağlı agamaglobulinemi (XLA) B hücrelerinin oluşumunu engelleyen genetik bir hastalıktır. İmmünoglobülin replasmanı ile ömür boyu tedavi gerektirir. Bu bireylerde olgun B hücrelerinin olmamasının COVID-19 seyrini olumsuz yönde etkileyebileceği düşünülmektedir. Toplumdaki bazı bireylerde olduğu gibi bu bireylerde COVID-19 enfeksiyonunu hafif atlatanlar görülmüştür. Bu çalışmada PCR ile COVID-19 tanısı konulan XLA hastalarının COVID-19 süreçleri ve bu hastalara uygulanan tedaviler ele alınmıştır.

Materyal ve Metot: Bu derlemede 15 Kasım 2021'e kadar PubMed, Web of Science, TRDizin ve Dergi Park web sitelerinde yayınlanan çalışmalar ele alındı. İngilizce ve Türkçe dilinde yapılmayan ve tam metni olmayan çalışmalar elendi. Bu çalışmalar arasından yalnızca XLA hastalarına ait COVID-19 olgu vakaları seçildi. Seçilen 16 makalede toplam 22 vaka incelendi.

Bulgular: Vakaların büyük çoğunluğunun COVID-19 süreçlerini daha ağır ve uzun süreli geçirdiği gözlemlendi. Bu hastalarda tedavi için antiviraller, anti-SARS-CoV-2 nötralize edici antikorlar ve immünomodülatör ajanlar kullanıldığı belirlendi.

Sonuç: XLA sahip bireylerde tedavi için antiviraller ve anti-SARS-CoV-2 nötrolize edici antikorların etkili olduğu düşünülmüştür. 

Anahtar Kelimeler

Bruton agamaglobulinemisi, Konvelasan plazma, X'e bağlı agamaglobulinemi, COVID-19, SARS-CoV-2

Düzeltme: COVID-19 treatment procedures applied to patients with X-linked agammaglobulinemia

Bu makalenin ilk hali 23 Aralık 2022 tarihinde yayımlandı. https://dergipark.org.tr/tr/pub/jomtu/issue/74065/1137147

Düzeltme Notu

Öz

Background: COVID-19 is a pandemic that started in 2019 and caused the death of many people. X-linked agammaglobulinemia (XLA) is a genetic disease that prevents the formation of B cells. This disease requires lifelong treatment with immunoglobulin replacement. It is thought that the absence of mature B cells in these individuals may adversely affect the course of the disease. As in some individuals in the society, it was seen that these individuals survived the disease mildly. In this study, the COVID-19 processes of XLA patients who were diagnosed with PCR and the treatments applied to these patients were discussed.

Materials and Methods: In this review, studies published on PubMed, Web of Science, TRDizin and Dergi Park websites until November 15, 2021 were discussed. Studies that were not made in English and Turkish languages and did not have full text were eliminated. Among these studies, only COVID-19 cases of XLA patients were selected. 22 cases were analyzed in 16 selected articles.

Results: It was observed that the vast majority of cases had more severe and prolonged COVID-19 processes. Antivirals, anti-SARS-CoV-2 neutralizing antibodies and immunomodulatory agents have used for treatment in these patients.

Conclusions: Antivirals and anti-SARS-CoV-2 neutralizing antibodies have been considered effective for treatment in individuals with XLA.

Anahtar Kelimeler

X-Linked agammaglobulinemia, Bruton agammaglobulinemia, COVID-19, SARS-CoV-2, Convalescent plasma

Kaynakça

• Almontasheri, A., Al-Husayni, F., Alsuraihi, A.K., Binyahib, H. & Albanna, A. S. (2021). The Clinical course of COVID-19 pneumonia in a 19-year-old man on intravenous immunoglobulin replacement therapy for X-linked agammaglobulinemia. Am J Case Rep., 22, e929447. https://doi.org/10.12659/AJCR.929447
• Atmar, R.L. & Finch, N. (2022). New perspectives on antimicrobial agents: molnupiravir and nirmatrelvir/ritonavir for treatment of COVID-19. Antimicrobial Agents and Chemotherapy, e02404-02421. Buckland, M.S., Galloway, J.B., Fhogartaigh, C.N., Meredith, L., Provine, N.M., Bloor, S., Ogbe, A., Zelek, W.M., Smielewska, A., Yakovleva, A., Mann, T., Bergamaschi, L., Turner, L., Mescia, F., Toonen, E. J.M., Hackstein, C.P., Akther, H.D., Vieira, V.A., Ceron-Gutierrez, L., . . . & Thaventhiran, J.E.D. (2020). Treatment of COVID-19 with remdesivir in the absence of humoral immunity:a case report. Nat Commun., 11(1), 6385. https://doi.org/10.1038/s41467-020-19761-2
• Cascella, M., Rajnik, M., Aleem, A., Dulebohn, S.C. & Di Napoli, R. (2022). Features, evaluation, and treatment of coronavirus (COVID-19). Statpearls [internet].
• Ciuffreda, L., Lorenzo-Salazar, J.M., Alcoba-Florez, J., Rodriguez-Perez, H., Gil-Campesino, H., Inigo-Campos, A., Garcia-Martinez de Artola, D., Valenzuela-Fernandez, A., Hayek-Peraza, M., Rojo-Alba, S., Alvarez-Arguelles, M.E., Diez-Gil, O., Gonzalez-Montelongo, R. & Flores, C. (2021). Longitudinal study of a SARS-CoV-2 infection in an immunocompromised patient with X-linked agammaglobulinemia. Journal of Infection, 83(5), 607-635., https://doi.org/10.1016/j.jinf.2021.07.028
• Devassikutty, F.M., Jain, A., Edavazhippurath, A., Joseph, M.C., Peedikayil, M.M.T., Scaria, V., Sandhya, P. & Govindaraj, G.M. (2021). X-Linked agammaglobulinemia and COVID-19: two case reports and review of literature. Pediatr Allergy
• Immunol Pulmonol, 34(3), 115-118. https://doi.org/10.1089/ped.2021.0002
• Guetl, K., Moazedi-Fuerst, F., Rosskopf, K., Brodmann, M., Krause, R., Eller, P., Wilhelmer, P., Eisner, F., Sareban, N., Schlenke, P., Kessler, H.H., Steinmetz, I., Redlberger-Fritz, M., Stiasny, K. & Stradner, M. (2021). SARS-CoV-2 positive virus culture 7 weeks after onset of COVID-19 in an immunocompromised patient suffering from X chromosome-linked agammaglobulinemia. J Infect., 82(3), 414-451. https://doi.org/10.1016/j.jinf.2020.10.025
• Hovey, J. G., Tolbert, D. & Howell, D. (2020). Burton's Agammaglobulinemia and COVID-19. Cureus, 12(11), e11701. https://doi.org/10.7759/cureus.11701
• Iaboni, A., Wong, N. & Betschel, S.D. (2021). A patient with X-linked agammaglobulinemia and COVID-19 infection treated with remdesivir and convalescent plasma. J Clin Immunol, 41(5), 923-925. https://doi.org/10.1007/s10875-021-00983-y
• Jin, H., Reed, J.C., Liu, S.T.H., Ho, H.E., Lopes, J.P., Ramsey, N.B., Waqar, O., Rahman, F., Aberg, J.A., Bouvier, N.M., Cunningham-Rundles, C. & Mount Sinai Health System Convalescent Plasma, T. (2020). Three patients with X-linked agammaglobulinemia hospitalized for COVID-19 improved with convalescent plasma. J Allergy Clin Immunol Pract., 8(10), 3594-3596 e3593. https://doi.org/10.1016/j.jaip.2020.08.059
• Lackey, A.E. & Ahmad, F. (2021). X-linked Agammaglobulinemia. In Statpearls. StatPearls Publishing [internet].
• Loh, S.Y., Bassett, J., Hoodless, E.J. & Walshaw, M. (2021). Possible COVID-19 reinfection in a patient with X-linked agammaglobulinaemia. BMJ Case Rep., 14(3), e240765. https://doi.org/10.1136/bcr-2020-240765
• Milosevic, I., Jovanovic, J. & Stevanovic, O. (2020). Atypical course of COVID-19 in patient with bruton agammaglobulinemia. J Infect Dev Ctries, 14(11), 1248-1251. https://doi.org/10.3855/jidc.13840
• Mira, E., Yarce, O.A., Ortega, C., Fernandez, S., Pascual, N.M., Gomez, C., Alvarez, M.A., Molina, I. J., Lama, R. & Santamaria, M. (2020). Rapid recovery of a SARS-CoV-2-infected X-linked agammaglobulinemia patient after infusion of COVID-19 convalescent plasma. J Allergy Clin Immunol Pract., 8(8), 2793-2795. https://doi.org/10.1016/j.jaip.2020.06.046
• Nguyen, H., Salkeld, J., Agarwal, S. & Goodman, A. (2021). Compassionate use of REGN-COV2 in the treatment of COVID-19 in a patient with impaired humoral immunity. Clin Infect Pract., 12, 100089. https://doi.org/10.1016/j.clinpr.2021.100089
• Palomba, E., Carrabba, M., Zuglian, G., Alagna, L., Saltini, P., Fortina, V., Hu, C., Bandera, A., Fabio, G., Gori, A. & Muscatello, A. (2021). Treatment of SARS-CoV-2 relapse with remdesivir and neutralizing antibodies cocktail in a patient with X-linked agammaglobulinaemia. Int J Infect Dis., 110, 338-340. https://doi.org/10.1016/j.ijid.2021.07.064
• Pereira, N.M.D., Heath, P.T., Doerholt, K., Almario-Hernandez, A.F., Gilmour, C. & Drysdale, S.B. (2021). SARS-CoV-2 infection in an adolescent with X-linked agammaglobulinemia. Pediatr Infect Dis J., https://doi.org/10.1097/INF.0000000000003360
• Soresina, A., Moratto, D., Chiarini, M., Paolillo, C., Baresi, G., Foca, E., Bezzi, M., Baronio, B., Giacomelli, M. & Badolato, R. (2020). Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover. Pediatr Allergy Immunol., 31(5), 565-569. https://doi.org/10.1111/pai.13263
• Speletas, M., Raftopoulou, S., Farmaki, E., Gatselis, N., Germanidis, G., Mouchtouri, V., Hatzianastasiou, S., Georgiadou, S., Tsinti, G., Tsachouridou, O., Tseroni, M., Metallidis, S., Dalekos, G., Eibel, H. & Hadjichristodoulou, C. (2021). B cells and COVID-19: Lessons from agammaglobulinemia patients and the study of functional B cell polymorphisms. J Investig Allergol Clin Immunol., 32(1). https://doi.org/10.18176/jiaci.0726.
• Uysal, P.İ. & Yalçın, B. (2018). İntravenöz immünglobulinlerin özellikleri ve uygulamada dikkat edilecek hususlar. Turkiye Klinikleri J Dermatol-Special Topics, 11(2),61-7.
• Wen, W., Chen, C., Tang, J., Wang, C., Zhou, M., Cheng, Y., Zhou, X., Wu, Q., Zhang, X. & Feng, Z. (2022). Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19：a meta-analysis. Annals of Medicine, 54(1), 516-523.